NewAmsterdam Pharma (NAMS) News Today $18.86 +0.14 (+0.75%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 4:01 PM | globenewswire.comNewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024July 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)July 18, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading VolumeNewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading VolumeJuly 14, 2024 | marketbeat.comTimesSquare Capital Management LLC Invests $5.41 Million in NewAmsterdam Pharma (NASDAQ:NAMS)TimesSquare Capital Management LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 228,616 shares of the company's stock, valuJuly 12, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 2%NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 2%July 9, 2024 | marketbeat.comJennison Associates LLC Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Jennison Associates LLC bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 930,851 shares of the company's stock, valued at approximately $22,015,000. JennisonJuly 8, 2024 | globenewswire.comNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk FactorsJuly 5, 2024 | seekingalpha.comNewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year PeriodJuly 4, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of "Buy" by AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objectJuly 3, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 5.6%NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 5.6%June 26, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseJune 25, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) CEO Buys $86,300.00 in StockJune 17, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.5%NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.5%June 15, 2024 | marketbeat.comOpaleye Management Inc. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Opaleye Management Inc. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 265,388 shares of the company's stock, valued at approximately $2,964,000. OpaleJune 13, 2024 | marketbeat.comParkman Healthcare Partners LLC Purchases 51,726 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Parkman Healthcare Partners LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 300,750 shares of the company's stock after buyiJune 11, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading VolumeNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseJune 7, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS)Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Friday.May 30, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Significant Decline in Short InterestNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 274,600 shares, a decline of 26.8% from the April 30th total of 375,000 shares. Based on an average daily volume of 180,500 shares, the short-interest ratio is presently 1.5 days. Currently, 0.4% of the shares of the stock are sold short.May 29, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneMay 21, 2024 | finance.yahoo.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsMay 17, 2024 | investing.comNewAmsterdam Pharma stock initiated with Buy rating by TD CowenMay 17, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)May 16, 2024 | msn.comTD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationMay 15, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12-month pricMay 10, 2024 | finance.yahoo.comNewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)May 9, 2024 | globenewswire.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 3, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | finance.yahoo.comNewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024April 30, 2024 | bloomberg.comOzempic Maker Novo Nordisk Has Denmark’s Economy HookedApril 30, 2024 | msn.comFTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicApril 23, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 6.7% Higher NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 6.7%April 16, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6%NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6%April 10, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 2.1%NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 2.1%April 9, 2024 | businesswire.comBioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of DirectorsApril 9, 2024 | globenewswire.comNewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseApril 8, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 4.9%April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)April 1, 2024 | globenewswire.comNewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerMarch 29, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $181,223.50 in StockMarch 29, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in StockMarch 28, 2024 | msn.comIf you loved NBC's ER, this new Max medical drama is the show for youMarch 28, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $181,223.50 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 8,429 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were bought at an average cost of $21.50 per share, with a total value of $181,223.50. Following the acquisition, the director now directly owns 3,008,429 shares in the company, valued at $64,681,223.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 27, 2024 | marketbeat.comJohannes Jacob Piete Kastelein Sells 190,476 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 190,476 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $21.50, for a total transaction of $4,095,234.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 25, 2024 | globenewswire.comNewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressMarch 19, 2024 | seekingalpha.comNAMS NewAmsterdam Pharma Company N.V.March 14, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Recommendation of "Buy" by AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have received an average recommendation of "Buy" from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-monthMarch 14, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Research Coverage Started at ScotiabankScotiabank started coverage on shares of NewAmsterdam Pharma in a report on Thursday. They issued a "sector outperform" rating and a $35.00 price objective for the company.March 13, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 3.1%NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 3.1% Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address We’re in a code red crisis and 99% of Americans are clueless (Ad)Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.580.62▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼42▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Elanco Animal Health News Krystal Biotech News Organon & Co. News Apellis Pharmaceuticals News Avidity Biosciences News Crinetics Pharmaceuticals News Immunovant News Arcellx News Xenon Pharmaceuticals News Merus News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
